Better Therapeutics Inc.’s prescription digital therapeutic (PDT) received U.S. FDA breakthrough device designation for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that increases the risk of cirrhosis, liver failure and liver cancer but has few good treatments available.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is characterized by accumulation of triglycerides (TGs) in liver hepatocytes, and which can progress into chronic liver disease or even hepatocellular carcinoma.
Kupffer cells are macrophages located in the liver that play a key role in liver pathology, concretely in metabolic dysfunction-associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease or NAFLD), but the mechanisms behind this are poorly understood.
Boehringer Ingelheim Pharma GmbH & Co. KG has identified 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Metabolic dysfunction-associated fatty liver disease, most commonly known as nonalcoholic fatty liver disease (NAFLD), has a prevalence of about 30% in the general population and about 80% in people with obesity. It is characterized by steatosis and metabolic dysfunction, with inflammation and fibrogenesis.
The FDA has cleared IND applications for UBT-251 injection, a long-acting triple-targeted glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon receptor agonist developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly owned subsidiary of The United Laboratories International Holdings Ltd., for adult type 2 diabetes and for overweight or obese subjects.
In a potential breakthrough for diagnosis and treatment development of liver disease, the Biomarkers Consortium’s Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) project demonstrated that a blood test could diagnose nonalcoholic steatohepatitis (NASH), an increasingly common liver disease in the U.S. The study, published in Nature Medicine, identified four biomarkers that outperform current liquid biopsies for NASH.
From shift workers to flight attendants, disruptions in circadian rhythms are a risk factor for metabolic disorders. Several sessions held at the recent EASL meeting focused on that link, and how disturbances in the internal clock may increase the risk of hepatic disorders.
Benobio Co. Ltd. has synthesized novel quinizarin derivatives acting as bromodomain and extra-terminal (BET) protein inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).
